Although no studies have directly investigated the application of TGF-β1-targeting drugs in CMBS, the bronchial wall fibrosis observed in CMBS shares high similarity in its core pathological mechanisms with other fibrotic diseases driven by TGF-β1, such as pulmonary fibrosis and systemic sclerosis. This evidence concerns the gene TGFB1 and pulmonary fibrosis.